pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 24·1 min read
save

AI doomsday warnings may curb health-tech innovation, Epic cautions

Sep 24, 2026·read at Endpoints ↗Negative

Recent commentary warns that sensational AI doomsday predictions could slow the pace of health‑technology innovation.

Epic, the large electronic health‑record company that provides AI tools to hospitals and clinicians, is cited as an example of a firm watching the narrative closely.

Analysts suggest the industry may adopt a more cautious stance toward AI deployment if fear dominates the conversation, potentially delaying new product rollouts.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “AI, doomsday, and slowing the pace of health tech innovation”

read at Endpoints ↗
84 words · retrieved Sep 24
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 13h agoAnthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and moreEndpoints
  • 1d agoSanofi may seek higher European drug prices, not withhold launches, under Trump dealEndpoints
  • 1d agoGilead CAR-T on partial clinical hold; Agios' PDUFA date pushed backEndpoints
  • 1d agoAstraZeneca says reorg could mean R&D cuts and trials shifted to emerging marketsEndpoints
  • 1d agoAnthropic's Nathan Frey on biopharma partners, M&A and pipelineEndpoints